The PTEN tumor suppressor regulates the PIK3CA/AKT1 pathway, and its inactivation significantly contributes to tumorigenesis and progression in hormone receptor-positive/HER2-negative (HR + /HER2 −) metastatic breast cancer (MBC). Here, ERBB2 is linked to neoplasm.